361 studies found for:    Open Studies | "Uterine Neoplasms"
Show Display Options
Rank Status Study
21 Recruiting Improving the Treatment for Women With Early Stage Cancer of the Uterus
Conditions: Complex Endometrial Hyperplasia With Atypia;   Grade 1 Endometrial Endometrioid Adenocarcinoma
Interventions: Drug: Levonorgestrel;   Drug: Metformin
22 Recruiting ADXS11-001 High Dose HPV+ Cervical Cancer
Conditions: Effects of Immunotherapy;   Metastatic/Recurrent Cervical Cancer;   Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Cervical Small Cell Carcinoma;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Intervention: Biological: ADXS11-001
23 Recruiting Lymphedema After Primary Surgery for Endometrial Cancer
Conditions: Carcinoma of the Endometrium;   Hysterectomy;   Lymphadenectomy
Intervention: Procedure: Lymphadenectomy
24 Recruiting Toxicities of Cervix and Corpus Uteri Carcinomas Treatment and Evaluation of Impact on Sexual Function
Condition: Corpus Uteri Carcinoma
Intervention:
25 Recruiting Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Metformin Hydrochloride;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
26 Recruiting Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -
Condition: Relapsed or Metastatic Uterine Leiomyosarcomas or Carcinosarcomas
Interventions: Drug: Pazopanib plus Gemcitabine;   Drug: Pazopanib
27 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
28 Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Glioblastoma;   Adult Soft Tissue Sarcoma;   Adult Solid Neoplasm;   Anaplastic Oligoastrocytoma;   Endometrial Serous Adenocarcinoma;   Estrogen Receptor Negative;   Estrogen Receptor Positive;   Hormone-Resistant Prostate Cancer;   Male Breast Carcinoma;   Metastatic Prostate Carcinoma;   Recurrent Adult Brain Neoplasm;   Recurrent Adult Hepatocellular Carcinoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Recurrent Uterine Corpus Sarcoma;   Resectable Hepatocellular Carcinoma;   Stage IA Breast Cancer;   Stage IA Ovarian Cancer;   Stage IA Uterine Corpus Cancer;   Stage IA Uterine Sarcoma;   Stage IB Breast Cancer;   Stage IB Ovarian Cancer;   Stage IB Uterine Corpus Cancer;   Stage IB Uterine Sarcoma;   Stage IC Ovarian Cancer;   Stage IC Uterine Sarcoma;   Stage II Uterine Corpus Cancer;   Stage IIA Breast Cancer;   Stage IIA Lung Carcinoma;   Stage IIA Ovarian Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Breast Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Lung Carcinoma;   Stage IIB Ovarian Cancer;   Stage IIB Skin Melanoma;   Stage IIB Uterine Sarcoma;   Stage IIC Ovarian Cancer;   Stage IIC Skin Melanoma;   Stage IIIA Breast Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Lung Carcinoma;   Stage IIIA Ovarian Cancer;   Stage IIIA Skin Melanoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Breast Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Skin Melanoma;   Stage IIIB Uterine Corpus Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Breast Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Skin Melanoma;   Stage IIIC Uterine Corpus Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Ovarian Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IVA Uterine Corpus Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Uterine Corpus Cancer;   Stage IVB Uterine Sarcoma
Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Drug: Sirolimus;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
29 Recruiting Suitability of DCE-MRI for Detection of Vascular Changes After VBT
Condition: Carcinoma of the Cervix, Carcinoma or Carcinosarcoma of the Uterus
Intervention: Radiation: Radiotherapy
30 Recruiting Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
Conditions: Endometrial Atypical Hyperplasia;   Endometrial Adenocarcinoma
Interventions: Drug: Megestrol acetate and metformin;   Drug: Megestrol acetate
31 Not yet recruiting Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers
Conditions: Cervical Carcinoma;   Ovarian Carcinoma;   Uterine Corpus Cancer;   Vaginal Carcinoma;   Vulvar Carcinoma
Interventions: Procedure: Supportive Care;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
32 Recruiting The Hysteroscopic Morcellator (HM).
Conditions: Large Intrauterine Polyps;   Smaller Type 0 and 1 Myomas;   Residual Placental Tissue
Interventions: Procedure: Hysteroscopic morcellator;   Procedure: Resectoscope
33 Recruiting Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Mucinous Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Endometrial Undifferentiated Carcinoma;   Endometrioid Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer;   Uterine Carcinosarcoma
Interventions: Drug: Carboplatin;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
34 Recruiting Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery
Conditions: Fallopian Tube Carcinoma;   Ovarian Carcinoma;   Primary Peritoneal Carcinoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Other: Comprehensive Geriatric Assessment;   Other: Questionnaire Administration
35 Recruiting Incidence of Malignant and Premalignant Endometrial Polyp in Asymptomatic and Symptomatic Postmenopausal Women
Conditions: Endometrial Polyp.;   Malignant and Pre-malignant Changes in the Polyp
Intervention: Procedure: Hysteroscopic polypectomy
36 Recruiting Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Conditions: Endometrial Adenocarcinomas;   Neuroendocrine Tumors;   Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy)
Interventions: Drug: lurbinectedin (PM01183);   Drug: Doxorubicin
37 Recruiting Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Cisplatin;   Radiation: Internal Radiation Therapy
38 Recruiting Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
Conditions: Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Mixed Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
39 Recruiting A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
Condition: Adenocarcinoma of the Endometrium
Intervention: Drug: Metformin
40 Recruiting Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia
Conditions: Complex Endometrial Hyperplasia With Atypia;   Stage IA Uterine Corpus Cancer;   Stage IB Uterine Corpus Cancer;   Stage II Uterine Corpus Cancer
Interventions: Behavioral: Weight Loss Specialist;   Other: Quality-of-Life Assessment;   Other: Medical Chart Review

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years